Search

Your search keyword '"Agewall S."' showing total 136 results

Search Constraints

Start Over You searched for: "Agewall S." Remove constraint "Agewall S." Database OAIster Remove constraint Database: OAIster
136 results on '"Agewall S."'

Search Results

1. Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium

2. Wytyczne ESC/ESH dotyczace postȩpowania w nadciśnieniu tȩtniczym (2018): Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) i Europejskiego Towarzystwa Nadciśnienia Tȩtniczego (ESH) do spraw postȩpowania w nadciśnieniu tȩtniczym

3. 2018 ESC/ESH guidelines for the diagnosis and treatment of arterial hypertension: The Task Force for the Diagnosis and Treatment of Arterial Hypertension of the European Society of Cardiology (ESC) and of the European Society of Hypertension (ESH)

5. Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review

6. Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium

7. Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review

8. Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review

9. Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: A review

10. Fourth universal definition of myocardial infarction (2018)

11. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Association for Cardiothoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM) [Linee guida ESC 2015 per il trattamento dell'endocardite infettiva: Task Force per il Trattamento dell'Endocardite Infettiva della Società Europea di Cardiologia (ESC): Con il patrocinio dell'Associazione Europea di Chirurgia Cardiotoracica (EACTS) e dell'Associazione Europea di Medicina Nucleare (EANM)]

12. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

13. ESC/ERS 2015 guidelines for the diagnosis and treatment of pulmonary hypertension

14. Prevalence of Anxiety and Depression Symptoms in Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries

15. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

16. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy

17. 2015 ESC Guidelines for the management of infective endocarditis

18. Artículo especial Guía ESC 2015 sobre el diagnóstico y tratamiento de las enfermedades del pericardio: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de las enfermedades del pericardio

19. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases

20. Automatic identification of variables in epidemiological datasets using logic regression

21. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis

22. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis

23. 2016 European Guidelines on the Prevention of Cardiovascular Diseases in Clinical Practice Sixth Joint Task Force of the European Society of Cardiology and other Societies on the Prevention of Cardiovascular Diseases in Clinical Practice (consisting of representatives of 10 companies and invited experts) drafted with the extraordinary contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR)

24. Automatic identification of variables in epidemiological datasets using logic regression

25. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)

26. 2016 European Guidelines on cardiovascular disease prevention in clinical practice

27. 2016 European Guidelines on cardiovascular disease prevention in clinical practice the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

28. 2016 ESC guidelines on cardiovascular disease prevention in clinical practice

29. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)

30. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration

31. Inflammatory markers and extent and progression of early atherosclerosis : Pooled analysis of individual participant data from 20 prospective studies of the PROG-IMT collaboration

32. The early diastolic myocardial velocity : A marker of increased risk in patients with coronary heart disease

33. Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy

34. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges

35. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy

36. Requirements for angiology/vascular medicine.

37. Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy

38. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges

39. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy

40. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy

41. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges

42. Requirements for angiology/vascular medicine.

44. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

45. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

46. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

47. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

48. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial.

49. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial.

50. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial.

Catalog

Books, media, physical & digital resources